Xencor, Inc. XE9.F Stock
Xencor, Inc. Price Chart
Xencor, Inc. XE9.F Financial and Trading Overview
Xencor, Inc. stock price | 21.4 EUR |
Previous Close | 24.2 EUR |
Open | 24 EUR |
Bid | 23.8 EUR x 50000 |
Ask | 24.2 EUR x 40000 |
Day's Range | 24 - 24 EUR |
52 Week Range | 20.2 - 34.6 EUR |
Volume | 90 EUR |
Avg. Volume | 0 EUR |
Market Cap | 1.46B EUR |
Beta (5Y Monthly) | 0.763028 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 53.55 EUR |
XE9.F Valuation Measures
Enterprise Value | 944.76M EUR |
Trailing P/E | N/A |
Forward P/E | -10.256411 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 14.903617 |
Price/Book (mrq) | 2.119954 |
Enterprise Value/Revenue | 9.636 |
Enterprise Value/EBITDA | -5.982 |
Trading Information
Xencor, Inc. Stock Price History
Beta (5Y Monthly) | 0.763028 |
52-Week Change | 20.79% |
S&P500 52-Week Change | 20.43% |
52 Week High | 34.6 EUR |
52 Week Low | 20.2 EUR |
50-Day Moving Average | 25.08 EUR |
200-Day Moving Average | 27.01 EUR |
XE9.F Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 60.39M |
Float | 54.71M |
Short Ratio | N/A |
% Held by Insiders | 0.86% |
% Held by Institutions | 105.25% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -142.31% |
Operating Margin (ttm) | -170.11% |
Gross Margin | -120.49% |
EBITDA Margin | -161.074% |
Management Effectiveness
Return on Assets (ttm) | -12.55% |
Return on Equity (ttm) | -19.29% |
Income Statement
Revenue (ttm) | 98.05M EUR |
Revenue Per Share (ttm) | 1.64 EUR |
Quarterly Revenue Growth (yoy) | -77.79% |
Gross Profit (ttm) | -34984000 EUR |
EBITDA | -157928000 EUR |
Net Income Avi to Common (ttm) | -139538000 EUR |
Diluted EPS (ttm) | -2.15 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 588.02M EUR |
Total Cash Per Share (mrq) | 9.74 EUR |
Total Debt (mrq) | 59.24M EUR |
Total Debt/Equity (mrq) | 8.67 EUR |
Current Ratio (mrq) | 9.684 |
Book Value Per Share (mrq) | 11.321 |
Cash Flow Statement
Operating Cash Flow (ttm) | -11944000 EUR |
Levered Free Cash Flow (ttm) | -21431250 EUR |
Profile of Xencor, Inc.
Country | Germany |
State | CA |
City | Monrovia |
Address | 111 West Lemon Avenue |
ZIP | 91016 |
Phone | 626 305 5900 |
Website | https://www.xencor.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 281 |
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb, which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
Q&A For Xencor, Inc. Stock
What is a current XE9.F stock price?
Xencor, Inc. XE9.F stock price today per share is 21.4 EUR.
How to purchase Xencor, Inc. stock?
You can buy XE9.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Xencor, Inc.?
The stock symbol or ticker of Xencor, Inc. is XE9.F.
Which industry does the Xencor, Inc. company belong to?
The Xencor, Inc. industry is Biotechnology.
How many shares does Xencor, Inc. have in circulation?
The max supply of Xencor, Inc. shares is 64.75M.
What is Xencor, Inc. Price to Earnings Ratio (PE Ratio)?
Xencor, Inc. PE Ratio is now.
What was Xencor, Inc. earnings per share over the trailing 12 months (TTM)?
Xencor, Inc. EPS is -2 EUR over the trailing 12 months.
Which sector does the Xencor, Inc. company belong to?
The Xencor, Inc. sector is Healthcare.